Sare Hosseini1, Jamshidkhan Chamani2, Hamidreza Rahimi3, Navid Azmoodeh2, Faezeh Ghasemi4, Porya Hassan Abadi5. 1. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Biology, Faculty of Sciences, Islamic Azad University-Mashhad Branch, Mashhad, Iran. 3. Department of Modern Sciences & Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Department of Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran. 5. School of Medicine, University of Birmingham, Birmingham, UK.
Abstract
BACKGROUND: The incidence of esophageal squamous cell carcinoma (ESCC) is increasing, causing catastrophic health burdens on communities. Curcumin has shown promise as a therapeutic agent in the treatment of colon, colorectal, pancreatic, and esophageal cancers but it has very poor bioavailability. The application of nano-carriers as drug delivery systems increases curcumin's bioavailability. Cyclin D1 is overexpressed in ESCC and curcumin may change its expression. METHODS: In this study, the effect of SinaCurcumin®, a novel nano-micelle product containing 80 mg curcumin, on the growth of KYSE-30 cells and expression of cyclin D1, was investigated. Paclitaxel and Carboplatin served as reference drugs. RESULTS: Nano-curcumin increased cell cytotoxicity, decreased IC50, and down-regulated of cyclin D1. However, treatment of cells with nano-curcumin might result in multidrug resistance. CONCLUSION: Nano-curcumin suppressed proliferation of KYSE-30 cells and expression of cyclin D1 although its use in combination with other chemotherapeutic agents requires further testing.
BACKGROUND: The incidence of esophageal squamous cell carcinoma (ESCC) is increasing, causing catastrophic health burdens on communities. Curcumin has shown promise as a therapeutic agent in the treatment of colon, colorectal, pancreatic, and esophageal cancers but it has very poor bioavailability. The application of nano-carriers as drug delivery systems increases curcumin's bioavailability. Cyclin D1 is overexpressed in ESCC and curcumin may change its expression. METHODS: In this study, the effect of SinaCurcumin®, a novel nano-micelle product containing 80 mg curcumin, on the growth of KYSE-30 cells and expression of cyclin D1, was investigated. Paclitaxel and Carboplatin served as reference drugs. RESULTS: Nano-curcumin increased cell cytotoxicity, decreased IC50, and down-regulated of cyclin D1. However, treatment of cells with nano-curcumin might result in multidrug resistance. CONCLUSION: Nano-curcumin suppressed proliferation of KYSE-30 cells and expression of cyclin D1 although its use in combination with other chemotherapeutic agents requires further testing.
Entities:
Keywords:
Curcumin; Cyclin D1 gene; Drug resistance; KYSE-30 cells; Nano-Micelle
Authors: Ricky A Sharma; Stephanie A Euden; Sharon L Platton; Darren N Cooke; Aisha Shafayat; Heather R Hewitt; Timothy H Marczylo; Bruno Morgan; David Hemingway; Simon M Plummer; Munir Pirmohamed; Andreas J Gescher; William P Steward Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: Ajaikumar B Kunnumakkara; Parmeswaran Diagaradjane; Preetha Anand; Kuzhuvelil B Harikumar; Harikumar B Kuzhuvelil; Amit Deorukhkar; Juri Gelovani; Sushovan Guha; Sunil Krishnan; Bharat B Aggarwal Journal: Int J Cancer Date: 2009-11-01 Impact factor: 7.396
Authors: Christopher D Lao; Mack T Ruffin; Daniel Normolle; Dennis D Heath; Sandra I Murray; Joanne M Bailey; Martha E Boggs; James Crowell; Cheryl L Rock; Dean E Brenner Journal: BMC Complement Altern Med Date: 2006-03-17 Impact factor: 3.659
Authors: Sare Hosseini; Jamshidkhan Chamani; Mohammad Reza Hadipanah; Negar Ebadpour; Amir Sajjad Hojjati; Mohammad Hasan Mohammadzadeh; Hamid Reza Rahimi Journal: Breast Cancer (Dove Med Press) Date: 2019-03-13